Kancera AB (publ) (Kancera) today reports the top-line results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer. The primary objective was met – to determine the...
Read MoreKancera AB (publ) (Kancera) today reports that it has completed a successful pre-IND meeting with the FDA and received positive feedback on the planned clinical development program for KAND567 in ST-elevation myocardial infarction. The FDA states that it agrees...
Read MoreThe period in brief – financial summary for the first quarter 2025 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 11,1 million (SEK 11,4 million). Operating loss for the quarter amounted to...
Read MoreKancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.
Read MoreKancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...
Read MoreThe period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the third quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 10,2 million (SEK 9,2 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the second quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 9,7 million (SEK 16,5 million). Operating loss for the quarter amounted to...
Read MoreThe period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...
Read MoreThe board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...
Read More